WS #16504
Eli Lilly reported strong Q3 revenue of $24.4 billion, driven by robust demand for diabetes and obesity medications, and raised its full-year guidance. Bristol Myers Squibb also lifted its sales outlook as newer drugs drive growth. This cluster highlights the continued strength of the GLP-1 and oncology markets, providing a defensive growth anchor for healthcare portfolios amidst macro uncertainty.
Healthcare and Biotech Catalysts
Eli Lilly reported strong Q3 revenue of $24.4 billion, driven by robust demand for diabetes and obesity medications, and raised its full-year guidance. Bristol Myers Squibb also lifted its sales outlook as newer drugs drive growth. This cluster highlights the continued strength of the GLP-1 and oncology markets, providing a defensive growth anchor for healthcare portfolios amidst macro uncertainty.